Verastem (NASDAQ:VSTM – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Verastem and AbbVie, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verastem | 1 | 0 | 11 | 0 | 2.83 |
| AbbVie | 0 | 6 | 22 | 1 | 2.83 |
Verastem presently has a consensus price target of $16.83, indicating a potential upside of 165.89%. AbbVie has a consensus price target of $299.62, indicating a potential upside of 4.69%. Given Verastem’s stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than AbbVie.
Profitability
This table compares Verastem and AbbVie’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verastem | -178.38% | -359.49% | -78.60% |
| AbbVie | 15.67% | -450.55% | 16.50% |
Valuation and Earnings
This table compares Verastem and AbbVie”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Verastem | $30.91 million | 25.81 | -$209.47 million | ($2.05) | -3.09 |
| AbbVie | $61.16 billion | 8.27 | $4.23 billion | $5.81 | 49.26 |
AbbVie has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Verastem has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500.
Insider and Institutional Ownership
88.4% of Verastem shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
AbbVie beats Verastem on 8 of the 15 factors compared between the two stocks.
About Verastem
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.
